Showing results (41-50 of 62) with videos related to
Sort By:
Pageof 7
Psycho-Oncology|June 5, 2015
The balance of clinician and patient input into treatment decision-making in older women with operable breast cancerJenna L Morgan, Maria Burton, Karen Collins, et al.Bioorganic & Medicinal Chemistry Letters|October 27, 2009
Discovery of highly potent and selective type I B-Raf kinase inhibitorsXiaolun Wang, Dan M Berger, Edward J Salaski, et al.Bioorganic & Medicinal Chemistry|September 26, 2008
4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitorsDan M Berger, Minu Dutia, Dennis Powell, et al.Cancer Biology & Medicine|January 19, 2016
The decision-making process for senior cancer patients: treatment allocation of older women with operable breast cancer in the UKJenna L Morgan, Paul Richards, Osama Zaman, et al.Bioorganic & Medicinal Chemistry Letters|November 4, 2009
Hit to lead optimization of pyrazolo[1,5-a]pyrimidines as B-Raf kinase inhibitorsAriamala Gopalsamy, Greg Ciszewski, Mengxiao Shi, et al.BMC Public Health|March 23, 2018
A scoping study of interventions to increase the uptake of physical activity (PA) amongst individuals with mild-to-moderate depression (MMD)Katarzyna Karolina Machaczek, Peter Allmark, Elizabeth Goyder, et al.Molecular Cancer Therapeutics|June 24, 2004
Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinaseRobert Mallon, Larry Feldberg, Steven Kim, et al.Journal of Medicinal Chemistry|January 11, 2002
Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1)Deniz Tasdemir, Robert Mallon, Michael Greenstein, et al.Patient Preference and Adherence|January 26, 2019
Efficient development and usability testing of decision support interventions for older women with breast cancerKate J Lifford, Adrian Edwards, Maria Burton, et al.Journal of Medicinal Chemistry|October 22, 2010
Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activityXiaolun Wang, Dan M Berger, Edward J Salaski, et al.Pageof 7